An Insight into Molecular Drug Targets of Helicobacter Pylori and Potential Therapies
Helicobacter pylori are a gram-negative spiral-shaped bacterium, belonging to the class Epsilonproteobacteria that colonizes the gastric epithelium of humans leading to a common infection that affects nearly 50% of the total population across the globe. They are the common bacteria that evade the gastric tract of humans causing numerous pathologies such as chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer. Usually, treatment of H. pylori is carried out using two or three antibiotics combined with a proton pump inhibitor. Recently, there is an increase in antibiotic resistance throughout the world and henceforth, there is an immediate need in identifying effective treatments. Identifying specific targets in H. pylori that are responsible for host-pathogen interactions, virulence factors etc., and developing specific drugs against them is one of the potential solutions. In doing so, it is important to understand in depth the structure and functions of the targets to develop drugs that are specific to them. This would lead to the effective eradication of the infection. In this review, we have identified 10 potential targets which are Urease, FlgE2, HtrA, Chorismate synthase, Peptide deformylase, VacA, Adhesin BabA, Csd4, Flavodoxins, รข-Clamp bound to DNA Ligase peptide. In future, effective drugs can be developed against these targets. Also, insights about the phytochemicals that are effective against H. pylori are mentioned in this review. Potential drugs combined with these phytochemicals can effectively eradicate the infection.